Humacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.
Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.24 per share a year ago.
Humacyte NASDAQ: HUMA reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from its prior day's close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.63, signifying a -6.44% move from its prior day's close.
In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.67, marking a +2.22% move from the previous day.
Humacyte, Inc. (HUMA) closed at $0.66 in the latest trading session, marking a -1.28% move from the prior day.
Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous trading session.